Cancer markers and detection methods

• US 20060194229A1
• Filed: 01/24/2006
• Published: 08/31/2006
• Est. Priority Date: 01/25/2005
• Status: Abandoned Application

• Current Assignee: Sky Genetics, Inc.
• Original Assignee: Sky Genetics, Inc.
• Inventors: North, Don Adams
• Application Number:
  US11/339,052
• Publication Number:
  US 20060194229A1
• Time in Patent Office: Days
• US Class Current: 435/6.14
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 15/1135 against oncogenes or tumor suppressor genes
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: G01N 33/574 for cancer

Abstract

The present invention relates to cancer markers and methods of detecting cancer markers in a sample. The sample may be peripheral blood. Cancer markers are most commonly mutated or abnormal DNA sequences associated with metastatic cancer. Markers may be detected using PCR, microarrays, or other nucleic acid or peptide-based assays. These methods may be used for a variety of diagnostic purposes, including initial, early-stage or later diagnosis of cancer, particularly metastatic cancer and monitoring of cancer or treatment progression. The cancer markers may also be used to create a cancer marker profile. Treatment may be directed based on this profile. Additionally, methods using blood may provide a cancer marker profile of mutations or abnormalities found in at least one of several tumors in the body, instead of merely one tumor. The invention also include kits, such as primer kits, and microarrays for use in performing the various methods.

Claims

1. A cancer detection reagent set comprising cancer detection reagents corresponding to at least 10 general cancer markers.

2. The cancer detection reagent set of claim 1, comprising cancer detection reagents corresponding to at least 50 general cancer markers.

3. The cancer detection reagent set of claim 1, comprising cancer detection reagents corresponding to at least 100 general cancer markers.

17. The cancer detection reagent set of claim 1, further comprising a microarray having the reagent set.

18. The cancer detection reagent set of claim 17, wherein the cancer markers are selected from the group consisting of:

colon cancer markers, lung cancer markers, lymph cancer markers, breast cancer markers, and any combinations thereof.

19. The cancer detection reagent set of claim 1, further comprising a PCR kit having the cancer markers.

20. The cancer detection reagent set of claim 19 wherein the cancer markers are selected from the group consisting of:

colon cancer markers, lung cancer markers, lymph cancer markers, breast cancer markers, and any combinations thereof.

4. A cancer detection reagent set comprising cancer detection reagents corresponding to at least 10 colon cancer markers.

5. The cancer detection reagent set of claim 4, comprising cancer detection reagents corresponding to at least 50 colon cancer markers.

6. The cancer detection reagent set of claim 4, comprising cancer detection reagents corresponding to at least 100 colon cancer markers.

16. The cancer detection reagent set of claim 4, comprising at least 50 cancer markers selected from the group consisting of cancer markers 3 and 55-66, and any combinations thereof.

7. A cancer detection reagent set comprising cancer detection reagents corresponding to at least 10 lung cancer markers.

8. The cancer detection reagent set of claim 7, comprising cancer detection reagents corresponding to at least 50 lung cancer markers.

9. The cancer detection reagent set of claim 7, comprising cancer detection reagents corresponding to at least 100 lung cancer markers.

10. A cancer detection reagent set comprising cancer detection reagents corresponding to at least 10 lymph cancer markers.

11. The cancer detection reagent set of claim 10, comprising cancer detection reagents corresponding to at least 50 lymph cancer markers.

12. The cancer detection reagent set of claim 10, comprising cancer detection reagents corresponding to at least 100 lymph cancer markers.

13. A cancer detection reagent set comprising cancer detection reagents corresponding to at least 10 breast cancer markers.

14. The cancer detection reagent set of claim 13, comprising cancer detection reagents corresponding to at least 50 breast cancer markers.

15. The cancer detection reagent set of claim 13, comprising cancer detection reagents corresponding to at least 100 breast cancer markers.

21. A method of detecting a cancer marker in a sample comprising:

extracting mRNA from the sample;

creating cDNA from the mRNA;

performing at least 10 separate PCR reduction reactions using the cDNA as a template and at least 10 different single primers, with a different single primer in each separate PCR reduction reaction; and

analyzing the product of each of the 10 separate PCR reduction reactions to determine the presence or absence of primer-amplified DNA molecules, where presence of primer-amplified DNA molecules in any PCR reduction reaction indicates the presence of a cancer marker;

wherein the 10 different single primers each have an antisense sequence corresponding to a different cancer marker.

22. The method of claim 21, where the sample comprises peripheral blood.

23. A method of detecting cancer markers in a sample comprising:

isolating sample nucleic acids from the sample;

placing the sample nucleic acids on a microarray having DNA molecules operable to detect and distinguish at least 10 corresponding cancer markers under conditions sufficient to allow detectable and specific binding of sample nucleic acids to complementary DNA molecules of the microarray; and

detecting binding of sample nucleic acids to the microarray,

wherein binding of sample nucleic acids to a DNA molecule on the microarray indicates the presence of a cancer marker corresponding to that DNA molecule in the sample.

24. The method of claim 23, wherein the sample comprises peripheral blood.